- Home
- STTK
STTK
Shattuck Labs Inc.
as of 03-18-2026 2:42pm EST
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | AUSTIN |
| Market Cap: | 275.9M | IPO Year: | 2020 |
| Target Price: | $7.60 | AVG Volume (30 days): | 589.2K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.70 | EPS Growth: | 53.02 |
| 52 Week Low/High: | $0.69 - $6.26 | Next Earning Date: | N/A |
| Revenue: | $1,000,000 | Revenue Growth: | -82.52% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -8.51 | Index: | N/A |
| Free Cash Flow: | -39953000.0 | FCF Growth: | N/A |
AI-Powered STTK Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 5, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLMar 5, 2026 · 100% conf.
1D
-2.10%
$4.55
Act: +17.65%
5D
-10.83%
$4.15
20D
-1.21%
$4.59
sttk-202603050001680367FALSE00016803672026-03-052026-03-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2026
Shattuck Labs, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3959381-2575858 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification Number)
500 W. 5th Street, Suite 1200 Austin, TX 78701
(Address of principal executive offices including zip code)
(512) 900-4690
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuance to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.0001 per shareSTTKThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act☐
Item 2.02 Results of Operations and Financial Condition
On March 5, 2026, Shattuck Labs, Inc. issued a press release announcing its financial results for the year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 incorporated herein shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits Exhibits
Exhibit NumberDescription of Exhibit
99.1Press release issued by Shattuck Labs, Inc. regarding its financial results for the year ended December 31, 2025, dated March 5, 2026
104The cover page from the Company’s Current Report on Form 8-K formatted in Inline XBRL.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Shattuck Labs, Inc.
Date: March 5, 2026 By:/s/ Dr. Taylor Schreiber
Dr. Taylor Schreiber Chief Executive Officer (principal executive officer)
3
2025 Q3 Q3 2025 Earnings
8-K/A SELL Nov 6, 2025 · 100% conf.
Q3 2025 Earnings
8-K/A SELLNov 6, 2025 · 100% conf.
1D
-3.08%
$1.90
5D
-11.82%
$1.73
20D
-14.31%
$1.68
sttk-202511060001680367TRUEThis Amendment to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 6, 2025 (the “Original 8-K”) is being filed to correct typographical errors in the Original 8-K.00016803672025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025
Shattuck Labs, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3959381-2575858 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification Number)
500 W. 5th Street, Suite 1200 Austin, TX 78701
(Address of principal executive offices including zip code)
(512) 900-4690
(Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuance to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.0001 per shareSTTKThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act☐
Explanatory Note: This Amendment to the Current Report on Form 8-K filed with the Securities and Exchange Commission on November 6, 2025 (the “Original 8-K”) is being filed to correct typographical errors in the Original 8-K. Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, Shattuck Labs, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 incorporated herein shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. Exhibits
Exhibit NumberDescription of Exhibit
99.1Press release issued by Shattuck Labs, Inc. regarding its financial results for the quarter ended September 30, 2025, dated November 6, 2025.
104The cover page from the Company’s Current Report on Form 8-K formatted in Inline XBRL.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Shattuck Labs, Inc.
Date: November 6, 2025 By:/s/ Dr. Taylor Schreiber
Dr. Taylor Schreiber Chief Executive Officer (principal executive officer)
3
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 6, 2025 · 100% conf.
Q3 2025 Earnings
8-K SELLNov 6, 2025 · 100% conf.
1D
-3.08%
$1.90
5D
-11.82%
$1.73
20D
-14.31%
$1.68
sttk-202511060001680367FALSE00016803672025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025
Shattuck Labs, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3959381-2575858 (State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification Number)
500 W. 5th Street, Suite 1200 Austin, TX 78701
(Address of principal executive offices including zip code)
(512) 900-4690
(Registrant’s telephone number, including area code)
Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuance to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Common Stock, par value $0.0001 per shareSTTKThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act☐
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, Shattuck Labs, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. As provided in General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 incorporated herein shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. Exhibits
Exhibit NumberDescription of Exhibit
99.1Press release issued by Shattuck Labs, Inc. regarding its financial results for the quarter ended June 30, 2025, dated August 14, 2025.
104The cover page from the Company’s Current Report on Form 8-K formatted in Inline XBRL.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Shattuck Labs, Inc.
Date: November 6, 2025 By:/s/ Dr. Taylor Schreiber
Dr. Taylor Schreiber Chief Executive Officer (principal executive officer)
3
Compare STTK vs Leading Stocks
See how STTK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "STTK Shattuck Labs Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.